Effect of Nitric Oxide on Oxygen Consumption of Skeletal Muscle by Cox, Christina Lyn
Virginia Commonwealth University
VCU Scholars Compass
Theses and Dissertations Graduate School
2006
Effect of Nitric Oxide on Oxygen Consumption of
Skeletal Muscle
Christina Lyn Cox
Virginia Commonwealth University
Follow this and additional works at: http://scholarscompass.vcu.edu/etd
Part of the Physiology Commons
© The Author
This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses
and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
Downloaded from
http://scholarscompass.vcu.edu/etd/1044
EFFECT OF NITRIC OXIDE ON OXYGEN CONSUMPTION OF 
SKELETAL MUSCLE 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science at the Medical College of Virginia Campus, Virginia Commonwealth University 
Christina Lyn Cox 
B.S., The College of William and Mary, 2000 
Director: 
Roland N. Pittman, Ph.D. 
Professor 
Department of Physiology 
Virginia Commonwealth University 
Richmond, Virginia 
August, 2006 
Acknowledgements 
First, I would like to thank Dr. Roland N. Pittrnan for his amazing patience, guidance, 
encouragement, and generosity, all of which are manifest daily in his remarkable 
mentoring and teaching skills. The atmosphere he creates of high morale, motivation, 
and learning clearly demonstrate his dedication to his students, laboratory, collaborators, 
and work. These few words can not express how grateful I am for what I have 
discovered over the past year. 
Secondly, I would like to thank the members of this laboratory, whose contributions 
made this project possible. Many thanks to Dr. Aleksander S. Golub, for whom this 
project would not be possible without his scientific wisdom and technical expertise. I 
give my thanks to Dr. Helena Carvalho, for her constant encouragement and willingness 
to lend a helping hand. I am very grateful for the patience and help of Dr. Michael A. 
Tevald who in the final stages of his experiments found time to impart significant 
surgical and methodological knowledge that allowed me to get to the point that I could 
even take measurements. I cannot thank Matthew Barker enough for his willingness to 
unselfishly extend his time to teach and instruct me on many occasions, to always listen 
to my frustrations, and to encourage me along the way. My thanks also extends toward 
Geoffrey Alexander, with whom in sharing not only office space but also experimental 
equipment we managed to not only remain sane but to become friends, providing advice 
and encouragement to complete our projects. 
I would also like to thank my graduate committee members, Dr. Joseph J. Feher, and Dr. 
Rakesh C. Kukreja, for without their time the completion of my project would not have 
been possible. 
Finally, I would like to thank my family for their support, encouragement, and interest in 
my project. Most of all, I would like to thank my parents who have allowed me to follow 
my dream which lead me to this adventure. 
Table of Contents 
. . 
............................................................................................................. Acknowledgements 11 
... 
............................................................................................................... Table of Contents 111 
. . List of Tables .................................................................................................................... vll 
... 
.................................................................................................................. List of Figures vlll 
... 
.................................................................................................................. List of Figures vlll 
............................................................................................................................... Abstract x 
Introduction ....................................................................................................................... 1 
............................................................................................ The Cardiovascular System 1 
Cellular Metabolism ........................................................................................................ 3 
..................................................................................................... Oxygen Consumption 4 
Blood Flow and Oxygen Consumption ....................................................................... 5 
Oxygen Transport ......................................................................................................... 6 
Nitric Oxide ................................................................................................................... 6 
Synthesis of NO ........................................................................................................... 7 
Actions of NO on Blood Vessels .................................................................................. 8 
Actions of NO on Mitochondria .................................................................................. 9 
.......................................................................... Rationale for Stop-Flow Experiments 10 
Materials and Methods ...................................................................................................... 11 
Preparation for Surgery ............................................................................................... 11 
............................................................................ Tracheal and Vascular Cannulations 12 
.................................................................. ........ Spinotrapezius Muscle Preparation . 15 
.................................................................................. ................................ Solutions . 18 
......................................................................................................... Stop-Flow Device 19 
................................................................................................. Video Microscopy 24 
................... Phosphorescence Quenching Microscopy . ............................................ 26 
.......................................................................................... Principle of the Method 26 
Preparation and application of the phosphorescent probe .................................. 27 
............................................................................. Hardware and Data Acquisition 28 
Localization of the Phosphor Probe ......................................................................... 31 
Flash Energy ........................................................................................................... 31 
Oxygen consumption by the method ............... . ...................................................... 31 
Experimental Protocol .................................................................................................. 35 
Calculation of Oxygen Consumption .......................................................................... 37 
Statistical Analysis ........................................................................................................ 38 
Results ............................................................................................................................. 39 
POz Time-Course during Stop-Flow Procedure ............................................................ 39 
Effects of L-NAME under Pentobarbital Anesthesia ................................................... 41 
............................................................................................................. Initial PIs,d2 41 
........................................................................................................ Minimum PIs,d2 41 
Duration of Hypoxia ................................................................................................. 42 
Recovery Peak PIS& ............................................................................................... 42 
Effects of L-NAME with Papaverine under Saffan Anesthesia ................................... 47 
vo. .......................................................................................................................... 47 
Initial P I S d 2  ............................................................................................................. 47 
Minimum P I&2 ....................................................................................................... 48
................................................................................................. Duration of Hypoxia 48 
Recovery Peak P1sf12 ............................................................................................... 48
ArteriolarDiameter ................................................................................................... 49 
Effect of Carboxy-PTIO + papaverine .......................................................................... 55 
vo2 .......................................................................................................................... 55 
............................................................................................................. Initial P d 2  55
Minimum P I s ~ 2  ....................................................................................................... 55 
................................................................................................. Duration of Hypoxia 55 
Recovery Peak P I s d 2  ............................................................................................... 56
Arterial Diameter ...................................................................................................... 56
....................................................................................... Effect of Spermine NONOate 61 
VO. .......................................................................................................................... 61 
Initial PlsflZ ............................................................................................................. 61 
.......................................................................................................... Minimum P d 2  
................................................................................................. Duration of Hypoxia 6 1 
Recovery Peak P I S d 2  ............................................................................................... 62 
Arteriolar Diameter .................................................................................................. 62 
...................................................................................................... Effect of Papaverine 68 
Initial PIS& ............................................................................................................ 68 
Minimum P 1 ~ 4 2  ........................................................................................................ 68 
Duration of Hypoxia ................................................................................................. 68 
Recovery Peak PIS& ............................................................................................... 69 
Arteriolar Diameter ................................................................................................. 69 
Discussion ..................................................................................................................... 77 
.................................................................................................... VO, and Altered NO 77 
........................................................ P1sF02 Time-Course during Stop-Flow Procedure 81 
Initial P1~F02 and Altered NO ....................................................................................... 81 
Minimum PISFOZ and Altered NO ................................................................................. 83 
Recovery Peak PI~FOZ and Altered NO ......................................................................... 84 
Arteriolar Diameter and Altered NO ........................................................................... 85 
Recommendations for Future Studies ........................................................................... 86 
Conclusions ................................................................................................................... 87 
References ......................................................................................................................... 88 
Appendix I ........................................................................................................................ 92 
Stop-Flow Bag Production ............................................................................................ 92 
......................................................................................... Preparation of the Saran bag 93 
Appendix I1 ...................................................................................................................... 94 
Vita ................................................................................................................................ 107 
List of Tables 
Table 1 . Effects of L-NAME under Pentobarbital ............................................................ 46 
Table 2 . Effects of L-NAME under Saffan ....................................................................... 54 
Table 3 . Effects of C-PTIO ............................................................................................... 60 
Table 4 . Effects of Spermine NONOate ........................................................................... 67 
Table 5 . Effects of Papaverine .......................................................................................... 74 
... 
Vl l l  
List of Figures 
................................................................................. Figure 1 . Canualae (Lowman 2004) 13 
....................... Figure 2 . The custom-built thermostatic heating platform (Loman 2004) 17 
Figure 3 Top: The Stop-Flow device connected to the n~icroscope and Bottom: The 
. . 
objective prepared with Saran bag .................................................................................... 21 
.................................................................. Figure 4 Diagram of Stop-Flow Compression 22 
Figure 5 . (Schleicher 2003) ............................................................................................... 23
Figure 6 . Schematic of the microscope set-up for intravital microscopy and 
phosphorescence quenching microscopy .......................................................................... 25 
Figure 7 . Representative phosphorescence decay curve ................................................... 30 
Figure 8 . Oxygen Consumption by the method (Tevald 2005) ........................................ 34 
Figure 9 . Phosphorescence PISFO2 Time Course .............................................................. 40 
Figure 10 . Effect of L-NAME (pentobarbital) on Oxygen Consumption ........................ 43 
Figure 1 1 . Effect of L-NAME (pentobarbital) on PISF02 ................................................ 44 
Figure 12 . Effect of L-NAME (pentobarbital) on Duration of Hypoxia ......................... 45 
Figure 13 . Effect of L-NAME on Oxygen Consumption ................................................. 50 
Figure 14 . Effect of L-NAME on PISF02 ........................................................................ 51 
Figure 15 . Effect of L-NAME on the Duration of Hypoxia ........................................ 52 
Figure 16 . Effect of L-NAME on Mean Arteriolar Diameter ........................................... 53 
Figure 17 . Effect of C-PTIO + PAPAVERINE on Oxygen Consumption ...................... 57 
Figure 18 . Effect of C-PTIO + PAPAVERINE on PIsFO2 ............................................... 58 
........................ . Figure 19 Effect of C-PTIO + PAPAVERINE on Duration of Hypoxia 59 
Figure 20 . Effect of Spermine NONOate on Oxygen Consumption ............................... 63 
Figure 2 1 . Effect of Spermine NONOate on PISF02 ...................................................... 64 
Figure 22 . Effect of Spermine NONOate on the Duration of Hypoxia ........................... 65 
Figure 23 . Effect of Spermine NONOate on Mean Diameter ........................................ 66 
Figure 24 . Effect of Papaverine on Oxygen Consumption ........................................ 70 
Figure 25 . Effect of Papaverine on PISFOZ ....................................................................... 71 
Figure 26 . Effect of Papaverine on the Duration of Hypoxia ........................................ 72 
Figure 27 . Effect of Papaverine on Arteriolar Diameter .................................................. 73 
Figure 28 . Effect of Various Treatments on Oxygen Consumption ................................ 75 
Figure 29 . Arteriolar Diameter Change with Various Experimental Treatments ............. 76 
Abstract 
EFFECT OF NITRIC OXIDE ON OXYGEN CONSUMPTION OF 
SKELETAL MUSCLE 
By Christina Lyn Cox 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science at Virginia Commonwealth University 
Virginia Commonwealth University, 2006 
Advisor: Roland N. Pittman, Ph.D. 
Department of Physiology 
Mammalian cells require a continuous and sufficient supply of oxygen to carry out their 
functions. The oxygen pathway has an overall direction taking O2 from the air to the 
mitochondria, which is a result of the mitochondria1 0 2  consumption (i'oz). NO has 
various effects on the mitochondria: at low concentrations for short periods NO 
specifically and irreversibly inhibits cytochrome c and reversibly inhibits cytochrome c 
oxidase, to decrease VO, . Thus, NO can modulate VO, of skeletal muscle. The purpose 
of the present study was to measure VO, of the rat spinotrapezius muscle under 
conditions of altered NO. The methods used provide a direct way to measure PO2 in the 
interstitium ( P I ~ F O ~ )  and use it as indicator of local metabolic changes. Intravital 
microscopy and phosphorescence quenching were used to record PISF02 in resting muscle 
for 120 s before, 60 s during, and 420 s after a period of tissue compression that abruptly 
halted perfusion. Control VO, measurements were made, followed by those in which the 
spinotrapezius muscle had been treated by topical application of agents known to alter 
NO levels (L-NAME, C-PTIO, Sperm/NO). The compression was achieved by rapid 
inflation of a Saran film air bag, attached to a X20 objective lens, which pressed the 
muscle against the animal platform. The rapid pressure onset (0-120 mmHg in < 1 s) 
arrested flow and squeezed out most of the blood from the observed muscle region. The 
albumin-bound Pd-MTCPP oxygen probe (10 mglml) was distributed in the interstitial 
space by exposure of both muscle surfaces for 30 min. A 276 pnl diameter spot in the 
muscle was excited through the objective lens. The rate of initial fall of PISFOZ, which 
started immediately after the airbag inflation, was used to calculate ~0~ and was based on 
the assumption that the amount of blood in the tissue after compression was small. 
Control VO, was 5.91 k 0.2 ml O2 . kg-'. min-'. Since the presence of RBCs sequestered 
in capillaries cannot be ruled out during compression, this value can be considered a 
lower limit for VO, by resting muscle. Comparison of baseline and treatment 
measurements of VO, showed no significant differences between them. This was 
unexpected based on in vitro studies and may reflect an impaired ability of the agents 
used to alter NO at the mitochondria1 level. 
Introduction 
The Cardiovascular System 
The primary function of the cardiovascular system is to deliver blood to the 
tissues, providing nutrients to the cells that are essential for metabolism and removing 
metabolic waste products. Mammalian cells require a continuous and sufficient supply of 
oxygen to carry out their functions. The cardiovascular system serves this need by 
supplying blood vessels in close proximity to the surface of most cells. 
One complete circuit of the cardiovascular system starts when oxygenated blood 
flows from the left atrium through the mitral valve to fill the left ventricle. The blood is 
then ejected from the left ventricle to the aorta and cardiac output is distributed among 
the various organs. Blood flow from the organs is collected in the veins and, since the 
pressure in the vena cava is higher than that in the right atrium, the right atrium fills with 
blood. Mixed venous blood then fills the right ventricle, flowing from the right atrium 
via the tricuspid valve. When the right ventricle contracts, blood is ejected to the lungs 
and oxygenated blood is then returned to the left atrium via the pulmonary vein. In 
general terms, blood is pumped from the heart though the arteries (distributing vessels) to 
the capillaries (exchange vessels) and into veins (collecting vessels) which lead back to 
the heart (Costanzo 2006). 
The microcirculation refers to the microscopic blood vessels, including the 
arterioles, capillaries, venules, and the neighboring lymphatic vessels. Because of the 
importance of this region, it has become the location and focus of many studies in the 
circulatory system. A microvascular unit begins with an arteriole, which is provided with 
a thin but compact sleeve of smooth muscle, allowing regulation of blood flow. The 
arterioles give rise to the capillaries that form a branching bed made up of a varying 
number of segments. Toward their venous end, the capillaries converge forming into 
venules that empty into veins. The exchange across the capillary wall of solutes and 
gases occurs via simple diffusion. Lipid soluble gases such as 0 2  and C02  readily cross 
the capillary wall by diffusion through the endothelial cells. Diffusion of a gas is driven 
by the partial pressure gradient between two sites. Blood functions as an intermediate 0 2  
carrier which connects the cells to an external gas exchanger (alveoli in the lungs). The 
oxygen binding properties of hemoglobin contained in the blood permit easy release of 
0 2  into the tissues, as well as efficient uptake in the lungs. To ensure an adequate 0 2  
supply to the mitochondria, organisms depend on O2 diffusion (i.e., the molecular 
movement of oxygen in the fluid or gas phase according to its partial pressure gradient), 
as well as on convective transport (i.e., the movement of oxygen in the blood by bulk 
flow) of 0 2 .  
Cellular Metabolism 
The three basic types of muscle are skeletal muscle, cardiac muscle, and smooth 
muscle. Skeletal muscle is striated muscle that is controlled by the central nervous 
system (voluntary control). The striations in skeletal muscle are the result of a highly 
organized arrangement of actin and myosin molecules. Skeletal muscle can be classified 
further as either fast twitch or slow twitch. Typically fast twitch fibers (types IIA , and 
IIB) and slow twitch fibers (type I) are intermixed in most mammalian skeletal muscles. 
Fast and slow twitch fibers can be distinguished by the activities of enzymes in the 
metabolic pathway utilized to form adenosine triphosphate (ATP). The activities of 
glycolytic enzymes are high and the activities of oxidative enzymes are low in most fast 
twitch fibers. These characteristics correlate with the number of mitochondria present in 
the fiber, as fast twitch fibers show only a few mitochondria compared with the large 
number seen in slow twitch fibers. Since fast twitch fibers depend on gycolytic 
metabolism, they fatigue rapidly. Slow twitch fibers meet their metabolic demands 
through oxidative phosphorylation, and are used for more sustained activity. Some fast 
twitch fibers (type IIA) found in mammals, although uncommon in humans, have both 
high glycolytic and high oxidative capacities. Fibers deriving their energy primarily from 
oxidative phosphorylation contain numerous mitochondria and high levels of the oxygen 
binding protein myoglobin (Berne and Levy 2004). 
Cellular metabolism liberates energy (primarily in the form of ATP) through a 
sequence of biochemical steps which take place either in the mitochondria or in the 
cytoplasm. All cells have the biochemical machinery to produce ATP. Carbohydrates 
are converted to pyruvate during glycolosis, and in the absence of oxygen, pyruvate is 
converted to lactic acid. When adequate oxygen is present, pyruvate is converted to 
acetyl-CoA and enters the Krebs cycle. Fatty acids are also converted to acetyl-CoA and 
enter the Krebs cycle, while protein metabolism products enter the Krebs cycle at various 
points in the cycle. The primary role in metabolism of the Krebs cycle is to produce 
reducing equivalents (primarily in the form of NADH) which act as electron carriers. 
Oxygen is utilized by the electron transport chain, a cascade of oxidation-reduction 
reactions which transfer the electrons carried by NADH to molecular oxygen, which then 
binds with hydrogen ions to produce water. The energy released by this series of 
reactions is used to make ATP. In addition to NADH, the electron-carrying molecules in 
the electron transport chain include FADH, ubiquinone, and the iron-carrying 
cytochromes. Electrons are transferred from cytochrome c to oxygen in the last step of 
the electron transport chain. The enzymes that comprise the electron transport chain are 
found in the mitochondria, and the mitochondria are therefore the destination for 
oxygen. It has been concluded from studies in muscles, in particular, that the 
mitochondrial content is a rate limiting factor for oxidative metabolism (Weibel 1984). 
Oxygen Consumption 
The oxygen pathway has an overall direction taking 0 2  from the air to the 
mitochondria, which is a result of the mitochondrial O2 consumption (vo,). If there 
were no VO,, the PO2 would soon become equal throughout the pathway; thus the 
mitochondria itself sets up the driving force. As long as the PO2 inside the cell is higher 
than approximately 1 mrnHg, the cellular and mitochondria1 VO, will not be limited due 
to the availability of oxygen. For oxygen to reach the mitochondria it must difhse fi-om 
the red blood cell (RBC) through several barriers, so that the PO2 must progressively fall 
from the RBC to the mitochondria. 
Blood Flow and Oxygen Consumption 
When looking at individual parts of the system, for example isolated skeletal 
muscle, we can consider a, in such a muscle to be equal to the rate of O2 entry into the 
tissue minus the rate of 0 2  exit. This statement is known as Fick's principle, whose 
fundamental assumption is that in the steady state cardiac output of the left and right 
ventricles is equal. Thus, 
Equation 1 
where VO, is the oxygen consumption, Q is the cardiac output, [O2Ia is the 0 2  content of 
arterial blood, and [O2Iv is the 0 2  content of venous blood. Fick's principle is not only 
applicable to the measurement of cardiac output or VO, (blood flow to the entire body), 
but it is also applicable to the measurement of VO, in organs or at the microcirculatory 
level. 
Oxygen Transport 
Oxygen is carried in the blood in two forms: dissolved and bound to hemoglobin. 
Dissolved oxygen, which accounts for only 2% of the total oxygen content in blood, is 
inadequate to meet the metabolic demands of the tissues. Thus, a second form of oxygen 
bound to hemoglobin is needed. Dissolved oxygen is the form of free O2 molecules 
which produces a partial pressure, and consequently drives 0 2  diffusion. According to 
Henry's law, the concentration of dissolved 0 2  is proportional to the PO2. The majority 
of the total oxygen content (98%) in blood is carried reversibly bound to hemoglobin. 
Hemoglobin consists of four subunits, two a chains and two P chains, and each subunit 
can bind one molecule of 02, for a total of four molecules of 02. Thus, blood serves as 
an 0 2  carrier, able to bind 0 2  easily and at high concentration, but not too tightly to make 
release into the tissue difficult (Weibel 1984; Costanzo 2006). 
Nitric Oxide 
Nitric oxide (NO) is a signaling molecule that performs a wide range of 
physiological processes. A signaling molecule binds selectively to a specific receptor in 
the classical scenario. However, NO does not hnction in the classical "lock and key" 
manner of a signaling molecule. NO signals via engaging chemical reactions with 
various protein targets. It is a simple gaseous molecule, the unitary combination of the 
two most abundant atoms in our atmosphere, which is lipophilic, reactive, and a free 
radical. The unpaired electron in its outer shell is the basis of NO'S biological activity. 
However, both the duration of exposure and the relative amount of NO produced 
influence the interactions of NO with other molecules. The lipophilic nature of NO 
allows its rapid diffusion through most cells and tissues. The net effect of NO is 
determined by the relative availability of alternative protein targets, the duration and 
amount of NO produced, and the microenvironment where NO is formed. The 
microenvironment plays a role in the complexity of NO signaling in that molecules in the 
intracellular and extracellular compartments compete to interact with NO. NO functions 
as a signaling molecule mediating vasodilation when produced in low concentrations by 
vascular endothelial cells, but when it is produced in high concentrations by 
macrophages, NO is used in apoptosis. It is thought that the main route in which NO is 
broken down in the blood is via the reaction of NO with hemoglobin in the red blood 
cells (RBCs) (Klem 1999). 
Synthesis of NO 
NO is synthesized by nitric oxide synthase (NOS), a dimer containing oxygenase 
and reductase domains linked by heme molecules. NOS yields equal quantities of NO 
and L-citrulline from L-arginine and oxygen, requiring NADH as an electron donor and 
both heme and calmodulin for activation of the enzyme. Calmodulin binding initiates a 
five electron oxidation, resulting in the production of ~ ~ - h ~ d r o x ~ - ~ - a r ~ i n i n e  as an 
intermediate, and finally NO and citrulline (Govers and Rabelink 2001). 
Two isoforms of NOS are constitutively expressed, termed neuronal NOS (nNOS) 
and endothelial NOS (eNOS), named for the tissues in which they were isolated. Their 
activity is predominately regulated by the changing levels of intracellular ca2+. In 
contrast, inducible NOS (iNOS) expression is induced by cytokines andlor oxidative 
stress. Once expressed, iNOS activity is continuous, high output, and ca2+ independent. 
There is some evidence that mitochondria may also contain NOS (mtNOS), however the 
nature of mtNOS and its relation to the other isoforms remains unclear (Frandsen, Lopez- 
Figueroa et al. 1 996; Ghafourifar and Richter 1997; Tatoyan and Giulivi 1998; Govers 
and Rabelink 200 1 ; Stamler and Meissner 200 1). 
Actions of NO on Blood Vessels 
Counterbalancing the vasoconstriction imposed by the sympathetic nervous 
system and the rennin-angiotensin system, NO is an important physiologic vasodilator. 
In response to stimuli, including endothelial shear stress and various endogenous 
vasorelaxants (i.e., acetylcholine, bradykinin, histamine, purines, leukotrienes and 
endothelin), NO is produced in the vascular endotheliurn by eNOS. In normal 
physiological processes this regulated production of endothelial NO serves as a 
homeostatic function for the control of blood pressure. NO is released from the 
endotheliurn as a paracrine messesnger, and works through a cGMP dependent pathway 
to phosphorylate the myosin light chain in smooth muscle cells, attenuating contractile 
tone and contributing to vasorelaxation. Inappropriate levels of NO can have remarkably 
deleterious effects. Septic shock is associated with NO overproduction in blood vessels, 
resulting from systemic bacterial infections. There is compelling evidence that the 
induction of iNOS is a key event to the etiology of septic shock. The continuous 
production of NO by iNOS and resulting high output causes extreme hypotension and 
often leads to multiple system organ failure. 
Endothelial NO also has antiatherogenic or vasoprotective actions on blood 
vessels. The NO released into the vascular lumen is an inhibitor of platelet aggregation 
and adhesion, thus providing protection against thrombosis, as well as attenuating the 
release of platelet derived growth factors which might otherwise promote smooth muscle 
proliferation and formation of atherosclerotic plaques. Various other antiatherogenic or 
vasoprotective actions of NO include decreased endothelial permeability, reduced influx 
of lipoproteins into the vascular wall and the inhibition of low density lipoprotein (LDL) 
oxidation. In combination, these findings suggest NO plays a significant role in 
maintaining the ability of the vasculature to deliver oxygen to tissues (Lane 2002). It is 
apparent that NO production within the blood vessels must maintain a delicate balance to 
achieve vascular health. 
Actions of NO on Mitochondria 
NO has various effects on the mitochondria: at low concentrations for short 
periods NO specifically and irreversibly inhibits cytochrome c and reversibly inhibits 
cytochrome c oxidase, but at higher levels of NO, more prolonged exposure to NO or 
conversion of NO to one of its more reactive oxides results in irreversible inhibition of 
respiration and other mitochondria1 damage (Brown 2001). Cytochrome c oxidase is 
responsible for approximately 90% of VO, and is essential for nearly all energy 
production in cells. NO competes with oxygen for the same biding site of cytochrome c 
oxidase. 
Rationale for Stop-Flow Experiments 
The purpose of the present study was to measure VO, of the rat spinotrapezius 
muscle under conditions of altered NO. The methods used provide an indirect way to 
measure PO2 in the interstitium (P1~~02)  and use it as indicator of local metabolic 
changes. The stop -flow device inflates a transparent bag to compress the tissue and 
squeeze blood out of the underlying vessels, thereby interrupting the source of 0 2  (blood 
flow stops) while VO, continues. Our search of the literature revealed no previous 
measurements of VO, under conditions of altered NO for a pefised tissue at the 
microcirculatory level. In the present study, VO, was measured under control and altered 
NO conditions. NO was decreased using multiple concentrations of a non-specific NOS 
inhibitor (L-NAME), as well as an NO scavenger (C-PTIO). A previous study in this lab 
showed no change in diameter or blood flow with L-NAME treatment in three arteriolar 
branching orders of the spinotrapezius microvasculature, but did show a decrease in PO2, 
suggesting NO has a significant effect on VO, . Thus, it was expected that VO, would 
increase following exposure of the muscle to L-NAME. However, this study found no 
significant difference from baseline VO, with decreased NO levels in either the case of 
topical treatment with L-NAME or C-PTIO. NO was increased using Spermine 
NONOate and it was expected that VO, , would decrease but we again found no 
significant difference from baseline measurements. 
Materials and Methods 
All procedures were approved by the Virginia Commonwealth University 
Institutional Animal Care and Use Committee and are consistent with the National 
Institutes of Health guidelines for the humane treatment of laboratory animals, as well as 
the American Physiological Society's Guiding Principles in the Care and Use of Animals. 
Preparation for Surgery 
Twenty-one female Sprague-Dawley rats (Harlan, Indianapolis, IN) weighing 
225-270 grams were housed in pairs in plastic containers and maintained on a 12: 12 hour 
light/dark cycle in a climate-controlled room (temperature 20-23 "C, humidity 40-60 %), 
and allowed access to food and water ad libitum under the supervision of a certified 
animal care technician. Female rats were used since their spinotrapezius muscles are 
thinner and contain less connective tissue than those of male rats, giving better image 
quality for intravital microscopy. 
In preparation for the experiment the animal was weighed on a triple beam 
balance and the mass was recorded. The animal was initially anesthetized with an 
intraperitoneal injection of a combination of Ketamine (75 m a g )  (Bedford Laboratories, 
Bedford, OH) and Acepromazine (2.5 m a g )  (Boehringer Ingelheim Vetmedica, Inc., St. 
Joseph, MO). The animal was then shaved along its neck and back with clippers, and a 
depilatory cream (Nair, Chrusch & Dwight Co., Inc., Princeton, NJ) was used to remove 
any remaining hair in the area. The animal was placed in the supine position on a 
homeothermic blanket set at 40 "C to maintain body temperature at 37 "C for 
cannulations and muscle exteriorization. 
Tracheal and Vascular Cannulations 
A set of vascular and tracheal cannulae were made from various sizes of 
polyethelene (PE) tubing (Figure 1). The right external jugular vein and the left common 
carotid artery were cannulated and used for continuous anesthetic infusion, mean arterial 
pressure measurement, and arterial blood sampling. Patency of cannulae was maintained 
with either a heparin lock (20 units of heparinlml of 0.9 % normal saline) or continuous 
infusion. Measurements were collected at 100 Hz using pressure transducers connected 
to a high-speed data acquisition system (MP150, BIOPAC Systems, Inc., Goleta, CA) via 
a RJ- 1 1 cable, transducer interface (TCI- 105, BIOPAC), and general purpose transducer 
amplifier (DAlOOC, BIOPAC). The acquisition system was connected to a personal 
computer (PC) equipped with a digital chart recorder (AcqKnowledge software, v3.7.3, 
BIOPAC). A tracheostomy tube was placed to maintain a patent airway. 
Figure 1. Canualae (Lowman 2004) 
Vascular and tracheal cannulae (A. Femoral arterial (PE 50-20-lo), B. Carotid artery (PE 
90-50), C. Femoral venous (PE 50), D. External jugular venous (PE go), E. Endotracheal 
(PE 190 with "bulb"), and F. Trachestomy (PE 240)). For the purposes of the present 
study only cannulae B,D, and F were utlilized. 
A small midline incision was made in the anterior neck over the trachea. The 
subcutaneous tissue was dissected, and the sternohyoid muscle was split longitudinally by 
blunt dissection to expose the trachea. The trachea was isolated, incised, and cannulated 
with polyethylene tubing (PE 240) to maintain a patent airway for the remainder of the 
experiment. The skin incision was then extended inferiorly and to the right in order to 
expose the jugular vein as it passed over the clavicle. The jugular vein was cannulated 
with polyethylene tubing (PE 90) for supplemental anesthetic infusion. At this point, 
continuous intravenous infusion of alfaxalone/alfadolone (Saffan, Schering-Plough 
Animal Health, Welwyn Garden City, UK; approximately 0.1 mg/kg/min) was initiated 
for maintenance anesthesia. In the initial part of this study, pentobarbital sodium () was 
used as the supplemental anesthetic in five experiments. Because of its known depressive 
effects on cardiovascular responses and metabolism, its use was discontinued. The 
anesthetic rate was adjusted as needed to maintain the surgical plane of anesthesia, as 
evidenced by the absence of a toe pinch reflex and stable vital signs (i.e., HR, MAP, and 
respiratory rate). 
The left carotid artery was then exposed in the crease between the sternohyoid 
muscle and the mastoid portion of the sternocephalic muscle. The left carotid artery was 
cannulated with a fluid-filled catheter constructed of a 3 cm length of PE 50 tubing 
affixed to a length of PE 90 tubing advanced down the carotid artery approximately 2 cm. 
Arterial pressure was measured continuously through the carotid artery catheter, which 
was also used for arterial blood sampling. 
Spinotrapezius Muscle Preparation 
The spinotrapezius muscle was used for measurement of microcirculatory 
hemodynamics and interstitial PO2 (PIS~02), and the surgical preparation was similar to 
the original description by Gray (Gray 1973; Bailey, Kindig et al. 2000). The 
spinotrapezius is a thin muscle that originates on the spinous processes of the thoracic 
and lumbar vertebrae and inserts on the scapula. The muscle is approximately 6 cm long, 
1.5 cm wide, and 500 pm thick. It has a mixed fiber type distribution (41% Type I, 7% 
Type IIA, 17% Type IIDK, 35% Type IIB) and a moderate oxidative capacity (citrate 
synthase activity 14 prn~l*rnin-~*~-'). A dorsal midline incision was initiated at the level 
of the lumbar vertebrae and extended superiorly to the level of the scapula, exposing the 
underlying superficial connective tissue. The underlying subcutaneous tissue was gently 
removed to minimize bleeding and prevent trauma to the underlying muscle. Bleeding 
was prevented or controlled during the exteriorization procedure by using a low - 
temperature cautery device (Gemini RS-300, Roboz Surgical Instrument Co., Rockville, 
MD), and the tissue was kept moist with frequent applications of Ringer's solution. As a 
further measure to prevent trauma to the preparation, a thin strap muscle running parallel 
to the lateral border of the spinotrapezius was used for surgical manipulation and 
suturing. The muscle was separated from deeper tissues along its lateral border by blunt 
dissection using Metzenbaum scissors. AEter the entire lateral border of the 
spinotrapezius muscle was gently separated fiom the underlying latissimus dorsi muscle, 
and the penetrating vessels at the caudal end were cauterized, a 7-8 cm long, 28-gauge 
wire, in the shape of a horseshoe (Suzuki 1995), was sutured to the lateral border at 8-10 
mm intervals using 5-0 silk sutures. The wire frame was used to ensure minimal trauma 
to the spinotrapezius, to facilitate surgical and experimental muscle manipulation, and 
maintain the muscle's physiological length during measurements. The dissection 
continued until the lateral, inferior, and medial borders were freed from the deeper 
muscle tissue, or cut from their attachments, and sutured to the wire frame, while the 
superior border was left intact. The muscle was superfused with Ringer's solution 
throughout the surgical procedure, and bleeding was controlled with the use of a cautery 
unit. This method of preparation leaves the supplying nerve and vasculature intact, and 
microvascular function is maintained. 
Once the spinotrapezius muscle was isolated, the animal was transferred to a 
custom-made thermostatic microscope platform originally described by Golub and 
Pittman (Golub and Pittrnan 2003) and modified by Lowrnan (Loman 2004) (Figure 2). 
The unit consisted of an adjustable platform for the animal's body and a pedestal onto 
which the spinotrapezius muscle was placed. Platform and pedestal temperatures were 
separately controlled by electronic heating units (Heaterstat temperature controller, model 
CT698-1005T39CL1, Minco Products, Inc., Minneapolis, MN), which were adjusted 
separately to maintain body and muscle temperatures at - 37 OC. The muscle tissue was 
moistened with Ringer's solution and covered with plastic film (Saran, Dow Corning, 
Midland, MI) to minimize desiccation and atmospheric gas exchange. In order to 
minimize the possibility of exposure of the preparation to the atmosphere, the wire frame 
was fastened to the pedestal and the plastic film was affixed to the pedestal with tape. 
Figure 2. The custom-built thermostatic heating platform (Loman 2004) 
Solutions 
A set of stock solutions were made for use in this set of experiments for later use 
in topical application to the spinotrapezius prep. The original N,-Nitro-L-arginine 
methyl ester hydrochloride (L-NAME) solution was made up of 10 mg of L-NAME 
(Sigma, St.Louis, MO) in 250 ml of distilled water to arrive at a final concentration of 40 
mgll. A second L-NAME solution was made up of 175 ml of the 40 mgll L-NAME 
solution and 75 ml of distilled water to arrive at a final concentration of 28 mgll. The 
Papaverine stock solution was made up of 38 mg of Papaverine in 100 ml of distilled 
water to arrive at a final concentration of 1mM. The N-[4-[I [(3[Aminopropyl)-2- 
hydroxy-2-nitrohydranzino]butyl]- 1,3-propanediamine (Spermine NONOate, SPERINO) 
stock solution was made of 25 mg of Sperrnine NONOate (Sigma, St. Louis, MO) and 
9.5 ml of 10 mM NaOH solution to arrive at a final Sperrnine NONOate concentration of 
10mM. The NaOH solution was made up of 0.1 ml of 1M NaOH in lOml of PBS. The 
2-(4-carboxyphenyl)-4,4,5,5-tetramethyl-imidazoline-l-oxyl-3-oxide potassiuni salt 
(carboxy-PTIO) solution was made up of 25 mg of carboxy-PTIO (Sigma, St.Louis, MO) 
in 79 ml of PBS to arrive at a final concentration of 1 mM. 
Stop-Flow Device 
In this study a unique device, designed by A.S Golub for a previous study to 
induce ischemia, was modified. The purpose of the device was to provide a rapid change 
in pressure that was uniformly distributed over the tissue, effectively halting blood flow, 
while at the same time not causing structural damage to the tissue (Figure 3). A pressure- 
generating device (pump) served to inflate and deflate a Saran bag surrounding the 
microscope objective. The control box contained a pressure gauge to monitor the 
pressure output, an ONIOFF switch, and a switch to generate a regulated pressure output 
of 120 mmHg of room air when turned on. The control box was fitted with tubing 
connected to a blunt needle. Surrounding the objective was a silicone sleeve 
approximately 40-60 rnm thick (see Appendix I for a description of its fabrication). The 
needle attached to the PE50 tubing was passed downward, lengthwise within the wall of 
the silicone sleeve. The sleeve held the tubing close to the objective and maintained an 
airtight seal. An inflatable bag was made from Saran film cut to loosely fit around the 
objective and silicone sleeve, and then made airtight with electrical tape (see Appendix I 
for description of its fabrication). The transparent Saran film served as a flexible material 
that did not interfere with the use of the objective. Since the Saran bag would be in 
contact with the Saran film placed over the spinotrapezius muscle, a transparent liquid 
lubricant (KY Touch ~ a s s a ~ e ~ ~  2-in-1 warmingTM, Personal Products Company, 
Division of McNeil-PPC, Inc., Skillman, NJ) was applied to reduce the friction between 
the two layers of Saran, thereby facilitating relative lateral movement between the 
objective and muscle, without concern of displacing the Saran placed over the muscle and 
possibly exposing the muscle to atmospheric air. Thus, the Saran bag could be rapidly 
inflated by applying pressure of 120 rnmHg to the surface of the spinotrapezius muscle, 
thereby stopping flow in the observed microvessels (Figure 4 and Figure 5). 
Esgare 3 Top: The SfopFlaw device connected to the microscope and Bottom: The objective 
prepued with Saran bag. 
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Figure 4 Diagram of Stop-Flow Compression 
Figure 5. (Schleicher 2003) 
Video Microscopy 
A 100-watt halogen lamp was used to transilluminate the muscle, and the 
microvasculature was observed with a Zeiss Axioplan 2 microscope equipped with 
Achroplan objectives (20X, NA=0.45). A Leitz 20X/NA 0.33 objective was adapted for 
use as a condenser. This set-up allowed Koller illumination to achieve excellent image 
quality. Images of the microcirculation were recorded on videotape (CCD-72 camera, 
MTI, Michigan City, IN; AG-DS555 VCR and Viero Flat Panel Monitor, Panasonic, 
Secaucus, NJ) with a total magnification of 1,100X at the monitor. The composite video 
signal from the camera was monitored on an oscilloscope. Centerline red blood cell 
velocity (v) was measured with an Optical Doppler Velocimeter (Cardiovascular 
Research Institute, Texas A&M Health Sciences Center, College Station, TX), and vessel 
luminal diameter (D) was measured with an image-shearing monitor (Model 908, 
Instrumentation for Physiology and Medicine, San Diego, CA). Output from both 
devices was recorded with a Biopac MP- 150 (200 Hz sampling rate), and measurements 
were averaged over 10 seconds. Figure 6 represents a schematic diagram of the 
microscope set-up. 
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Figure 6. Schematic of the microscope set-up for intravital microscopy and phosphorescence 
quenching microscopy. 
Phosphorescence Quenching Microscopy 
Principle of the Method 
Phosphorescence quenching microscopy (PQM) is a non-invasive, optical 
technique that can measure POz with a high degree of spatial and temporal resolution. It 
utilizes a phosphorescent molecule as an oxygen probe that can be injected into the 
vasculature or topically applied to the tissue. When excited by light, phosphorescent 
molecules are raised to the triplet state and return to the ground state by emitting light, a 
process known as phosphorescence. Additionally, the molecule can return to the ground 
state by transferring energy to other molecules, thereby decreasing the duration of the 
phosphorescence decay-a process known as quenching. Oxygen is the principal 
quenching agent in biological tissues, and the rate of quenching is diffusion-limited. The 
oxygen dependence of the phosphorescence decay is described by the Stern-Volmer 
equation: 
Equation 2 
where T is the lifetime at the measured POz, To is the phosphorescence lifetime in the 
absence of oxygen, and k, is the quenching coefficient. However, in the presence of 
oxygen gradients, as occur in vivo, the use of the Stern-Volmer equation can lead to 
systematic underestimates of POz. Golub et a1 (Golub, Pope1 et al. 1997) proposed a 
model (Rectangular distribution) that accounts for non-uniform oxygen levels in the 
measurement region and, therefore, minimizes the systematic error inherent in PO2 
determinations using a monoexponential function. Final PlSF02 values were calculated 
using the following equation: 
Equation 3 
I@)= 1(0)exp[- (k,, + kq~)].sinh(kqd)l(kqd)+   ex^(- t IT)+ B 
where t (ps) is the time from the beginning of phosphorescence decay, I(?) (volt) is the 
magnitude of the phosphorescence signal, I(0) (volt) is the amplitude of the 
phosphorescence signal at t = 0, l c ~  is the phosphorescence decay rate in the absence of 
oxygen (h = llzo), k, is the quenching coefficient, M (mmHg) is the mean PO2, 6 is the 
half-width of the PO2 distribution, A (volt) is the amplitude of the fast post-excitation 
transient, T (ps) is the lifetime of the fast post-excitation transient, and B is the baseline 
offset. The values for constants ko and k,, 18.3.10-~ ps-' and 3.06.10-~ p s - l m m ~ ~ - l ,  
respectively, were determined by Zheng et al.(Zheng, Golub et al. 1996) 
Preparation and application of the phosphorescent probe 
The excitation spectrum for palladium meso-tera-(4-carboxyphen1y)-porphyrin 
(Pd-MTCPP; Oxygen Enterprises, Philadelphia, PA) has two peaks @ 410 and 523 nm. 
This study employed an excitation wavelength of 525 nm, which allowed deeper 
penetration through tissue than the shorter wavelength. The emission spectrum for Pd- 
MTCPP has a wide peak between 650 and 750 nm. 
For the purposes of this experiment Pd-MTCPP was prepared bound to albumin. 
Preparation of 20 ml of albumin-bound phosphorescent probe solution (1 0 mglml) 
required binding of 200 mg Pd-MTCPP to 1.32 g bovine serum albumin (BSA; Fraction 
V, Sigma, St.Louis, MO). Over approximately 30 minutes the Pd-MTCPP was added to 
a 1mM BSA solution and stored overnight. The solution was dialyzed in 1 mM 
polyvinylpyrrolidine solution (PVP; Sigma, St.Louis, MO) and SpectrafPor-4 membranes 
to remove any unbound Pd-MTCPP from solution. After 18 hours the solution was 
removed from the dialysis membranes and filtered through a sterilization filtration unit 
(Nalgene, Rochester, NY). Aliquots of 0.5 ml of the final probe solution were placed in 
micrcentrifuge tubes, flash frozen on dry ice, and promptly stored at -80 OC. 
The probe was thawed just phor to application. The probe was then applied to 
filter paper and topically exposed to both surfaces of the spinotrapezius muscle for 30 
minutes, a time sufficient for its diffusion to a depth of 200 pm. The muscle was covered 
with Saran film, and the animal was covered with black felt to reduce exposure to 
ambient light. 
Hardware and Data Acquisition 
A Zeiss Axioplan 2 microscope was configured for epi-illumination using a Zeiss 
Achroplan objective (20X, NA 0.45). A xenon flash lamp (FX-249, EG&G 
Optoelectronics, Salem, MA) with an output of 0.5 Jlflash, 3 ps duration, and a flash rate 
of 1 Hz was used to excite the probe in an area of tissue 276 pnl in diameter. The light 
energy was reduced by 75% with an OD 0.6 filter (model 46214, Edmund Industrial 
Optics, Barrington, NJ), and the excitation wavelength was selected by passing the flash 
of light through a 525 nm band pass filter with a 70 nm bandwidth (Intor Inc, Socorro, 
NM). The light was then reflected through the objective and onto the tissue. The 
resulting phosphorescence emission was collected by the objective and passed through a 
650 nm cut-on filter (Oriel Corp., Stratford, CA) before detection by a photomultiplier 
tube. Output from the photomultiplier tube was sent to an analog-to-digital converter 
(SCB-68, National Instruments, Austin, TX), which was connected to a personal 
computer. The output was also monitored on an oscilloscope (model 72-3055, Tenma 
Test Equipment, Springboro, OH) in order to ensure that the maximum signal was - 8 V 
so as not to saturate the analog-to-digital converter, whose maximum input was 10 V. 
A customized computer was used to acquire and process the signal from 
the analog-to-digital converter at a sampling rate of 200 kHz. Four hundred points were 
collected for each curve, and the curves were saved for off-line analysis. Each curve was 
analyzed according to the Rectangular model described above using another customized, 
automated analysis program employing the nonlinear least-squares method of Marquardt- 
Levenburg (Lab View 7, National Instruments Co., Austin, TX). The high signal-to- 
noise ratio obtained using this system obviates the need to average multiple curves to 
obtain an accurate PISFOZ measurement. Figure 7 illustrates a representative individual 
phosphorescence decay curve. 
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Figure 7. Representative phosphorescence decay cuwe 
The phosphorescence decay curve shown on a logarithmic scale is composed of 400 
connected data points taken at 200 kHz over 2000 ps. The decay curve was analyzed 
using a non-linear curve fitting, the Rectangular distribution model and is shown here by 
the continuous line fit. 
Localization of the Phosphor Probe 
Since the Pd-MTCPP probe is bound to albumin, it was expected to remain in the 
interstital space. The large molecular weight of the albumin-bound molecule would 
prevent it from entering cells, and the hydrostatic pressure in the blood vessels would 
prevent it from entering the vasculature. Furthermore, if any Pd-MTCPP probe were to 
enter the vascular space, it would be swept away by the flowing blood. 
Flash Energy 
The light energy at the tissue was measured using a commercially available sensor 
(Lasercheck, Coherent, Auburn, CA). A flash rate of 100 Hz was used for this 
measurement to accommodate the Lasercheck instrument. Power was calculated as 1.33 
h 0.01 pW. The excitation area on the tissue was 276 pm in diameter or 5.98 . lo4 cm2. 
Energy density per flash was therefore 0.22 - lo4 J . cm-*. 
Oxygen consumption by the method 
Photoactivated consumption of oxygen occurs as a result of the excited state 
molecule interacting with oxygen to produce singlet oxygen and superoxide, and can lead 
to a reduction in the PO2 at the measurement site. While this effect is negligible in the 
vasculature, where each flash excites a new volume of flowing blood, it is of particular 
importance in the case of repeated measurements in a stationary volume of tissue as is the 
case in the current study. In order to determine the degree of oxygen consumption due to 
the PQM method in the current situation, in a prior study the spinotrapezius muscle from 
one rat was saturated with the Pd-MTCPP probe, then excised from the animal and killed 
by repeated freeze-thaw cycles. The tissue was exposed to room air, and then sealed in 
Saran, which is impermeable to oxygen. Using the same parameters as those described 
for the experiment, a PISFO2 measurement was made once a second for 1000 s. The 
resulting POz profile is illustrated in Figure 8 (Tevald 2005). Since there was no source 
of oxygen, the PISFO2 at the measurement spot fell until it reached near zero. From this 
profile, a consumption rate of 0.3 1 mm~~aflash- '  was calculated for the PQM method. 
While this is a negligible degree of consumption, the time in between flashes must be 
long enough for diffusion to replenish local oxygen. The critical interflash interval (T) 
can be estimated with the following equation: 
Equation 4 
where x is the linear dimension of the excitation region, and D is the diffusion 
coefficient for oxygen (2-10" cm2-sec-'). In perfused tissue, the region of tissue excited 
by the flash is composed of many subregions, each with its own oxygen source (i.e., a 
capillary). Capillary density in the spinotrapezius is 400 making intercapillary 
distance 50 p. Assuming that each capillary perfuses an area of tissue halfway between 
it and the next capillary, each subregion is 25 pn wide. The resulting critical T is thus 
156 ms. With a flash rate of 1 Hz, the interflash interval is more than sufficient to allow 
diffusion to replenish any oxygen consumed by the flash. The lack of a systematic 
decline in resting PIsFOZ values during the in vivo experiments supports the conclusion 
that this small degree of consumption is negligible. 
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Figure 8. Oxygen Consumption by the method (Tevald 2005) 
Experimental Protocol 
Prior to each set of oxygen consumption (vo,) measurements systemic 
measurements were ta.ken, including mean arterial pressure (MAP), heart rate (HR), 
arterial pH, arterial PC02, arterial P02. A bag-inflation test was performed prior to each 
set of m, measurements to ensure that flow was stopped before collecting PO2 data. 
Measurements were collected at six sites per condition. Measurement sites were chosen 
such that mostly capillaries were in the field of view, avoiding large vessels. Arteriolar 
diameter and RBC velocity were measured in the arteriole closest to the VO, prior to 
collecting PO2 data. To improve optical clarity of these measurements, a different X20 
Zeiss objective was used that did not have the saran bag attached. The fractional change 
in arteriolar diameter from control was calculated according to: 
Equation 5 
where dc is the diameter of the vessel under control conditions and dT is the diameter of 
the vessel after treatment. An initial PISFO2 measurement consisting of 10 curves was 
performed to verify that the PISF02 at the chosen site was between 20-70 mmHg before 
proceeding with the stop-flow measurement. The stop-flow measurement consisted of 
600 curves taking 10 minutes to collect (i.e., one curve per second). Baseline PISFO2 was 
measured for 2 minutes, and then the power to the stop-flow device was turned on 10 
seconds prior to initiating bag-inflation. Bag-inflation was initiated at the 2-minute point 
and lasted for 1 minute. Circulation under the inflated bag stopped within 1 second after 
the step rise in pressure and resumed immediately after bag deflation, 1 minute later. The 
power was shut off to the device 30 seconds following pressure release. 
After the baseline measurements were collected, the animal was removed from 
,the microscope platform for topical application of an experimental agent. The Saran film 
was removed, and the spinotrapezius muscle was exposed to filter paper soaked with the 
treatment agent for 12 seconds or 2 minutes depending on the dose. Following topical 
exposure to the treatment agent, a few drops of Ringer's solution were placed on the 
muscle prior to recovering the muscle with Saran film. Systemic measurements were 
recorded following the treatment.   he initial L-NAME experiments were done by 
topically applying filter paper soaked with the 40 mgll solution for 12 seconds for the 
first dose resulting in a 10 mgll concentration in the tissue, and 2 minutes for the second 
dose resulting in a 30 mgll concentration in the tissue. Initial testing resulted in low 
PISFOZ (< 20 mrnHg) , and it was determined that papaverine, an NO-independent smooth 
muscle relaxant, should be added to the L-NAME application to counteract the 
vasoconstriction produced by L-NAME. The L-NAME + papaverine "cocktail" consisted 
of 10 ml of 40 mgll L-NAME and 1 ml of 1mM papaverine. The "cocktail" was used in 
the same manner as the L-NAME treatment previously discussed. Further testing 
continued to result in low PISFOZ at the high (30 mgll) dose of L-NAME, and it was 
decided to use a single lower dose of L-NAME. The L-NAME + papaverine "cocktail" 
consisted of 28 mgll 1-NAME and 1mM and the tissue was only exposed for 12 seconds. 
In the experiments using papaverine alone, the muscle was exposed to filter paper soaked 
in 1mM papaverine for 12 seconds, resulting in a 100 pM concentration in the tissue. In 
the Sperm/NO experiments, 0.1 ml of the 10 rnM stock solution of Sperm/NO was 
diluted in 2.4 ml of PBS to end up with a final concentration of 100 pM. The C- PTIO 
experiments exposed the muscle to a "cocktail" consisting of 0.1 ml of papaverine, 0.4 ml 
of 1mM C-PTIO, and 0.5 ml of PBS resulting in a 400 pM C-PTIO concentration and 
100 pM concentration of papaverine in the tissue. 
Calculation of Oxygen Consumption 
For each PISFO2 time-course, the slope of the PO2 decline during bag-inflation was 
calculated. A region was chosen where there was a continuous decline that did not fall 
below 10 mmHg, typically consisting of 10 points, to calculate dPO21dt. VO, is related to 
dP02/dt through the factor a02, the solubility of 02, whose value is 1.745 ml Oz . kg-'. 
mmI-lg-' (Golub 2005). Oxygen consumption was calculated as: 
Equation 6. 
Since the presence of RBCs sequestered in capillaries cannot be ruled out during the 
bag-inflation, this value of VO, can be considered a lower limit for the resting muscle. 
Statistical Analysis 
Data from these experiments are presented as mean k standard error in tables and 
figures. JMP version 4.0.4 (SAS Institute, Inc., Cary, NC) was used to perform 
significance tests (analysis of variance on multiple factors and unpaired t-test between 
two independent means); actual P values are reported with the level of significance taken 
to be <0.05. 
Results 
POz Time-Course during Stop-Flow Procedure 
A representative PISF02 time-course during the stop-flow procedure is shown in 
Figure 9. During the baseline period (0-120 seconds), the PISF02 values appear stable. 
After compression was initiated, PIsFOZ fell rapidly until a new steady state PISF02 was 
achieved. When compression ended (at 180 s), PISFOZ increased rapidly, reaching a peak 
recovery P I ~ F O ~  higher than the baseline steady state, and eventually returned back to the 
baseline level. 
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Figure 9. Phosphorescence PIsFOZ Time Course 
AI: initial PISF02 interval, AII: interval from bag inflation to bag deflation AIII: interval 
from bag deflation to recovery peak PISF02, AIV: interval from recovery peak PISF02 
to return to average PISF02. 
BI: fall of PISF02, BII: minimum PISF02 during compression, BIII: Peak Recovery 
PISF02. 
C: linear fit used to determine V O ~  
Effects of L-NAME under Pentobarbital Anesthesia 
vo, 
Control measurements in this group of animals (n = 5) using pentobarbital as the 
anesthetic, exhibited VO, of 6.5 l* 0.62 m102 . kg-'. min-'. In the same animals VO, was 
5.74 * 0.97 m102 . kg-'- min-' after the initial 10 mglkg dose of L-NAME (Figure 10). 
The two values were not significantly different (P = 0.54) (Figure 10) 
Initial PIS& 
Initial average PISFOZ measurements exhibited a significant (P = 0.0004) decrease 
fiom the control value (63.5 * 3.78 mrnHg) to 32.0 & 4.7 mmHg following the initial 10 
mgll dose of L-NAME (Figure 11). 
Minimum PIS@2 
The minimum PISFO2 for control (1.5 h 0.6 mrnHg) and L-NAME (1.0 * 0.2 
mrnHg were not significantly different (P = 0.86) (Figure 11). 
Duration of Hypoxia 
The duration of hypoxia, which was defined as the time period when PISFOZ was 
less than or equal to 5 mrnHg, was not significantly different (p = 0.24) for the control 
(45 k 3) s, and L-NAME groups (57 k 5 s) (Figure 12). 
Recovev Peak PIS& 
The recovery peak PISF02 significantly decreased fiom 77.6 * 5.3 mmHg for the 
control group to 47.1 9.3 mmHg for the L-NAME group (P = 0.0 1) (Figure 1 1). 
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Figure 10. Effect of LNAME (pentobarbital) on Oxygen Consumption 
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Figure 11. Effect of L-NAME (pentobarbital) on PISFOl 
* Indicates a significant difference between control and treatment conditions. 
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Figure 12. Effect of L-NAME (pentobarbital) on Duration of Hypoxia 
Variables L-NAME Control 
F@, ml02 - kg-'- min-' 6.51 * 0.62 5.74 k 0.97 
Initial mmHg 63.5 k 3.78 32.0 h 4.7 
Minimum PIsflz, mmHg 1.5 k 0.6 1 .O zk 0.2 
Duration of Hypoxia, sec 45 =k 3 57 * 5 
Recovery Peak PISf12, mmHg 77.6 h 5.3 47.1 k 9.3 
Table 1. Effects of L-NAME under Pentobarbital 
Effects of L-NAME with Papaverine under Saffan Anesthesia 
vo2 
1 Control VO* using saffan as the anesthetic was 6.80 h 0.35 ml O2 - kg-'- mid . 
The low L-NAME (7 mg/l) + papaverine dose yielded VO, 6.38 k 0.50 ml02 . kg-'- min- 
', the intermediate dose of L-NAME (10 mg/l) + papaverine 5.86 k 0.50 mlO2 kg-'. 
mid1, and the high L-NAME (30 mgll) + papaverine dose 6.29 k 0.66 mlO2 . kg-'. mid' 
(Figure 12). VO, at any of the three different L-NAME + papaverine doses was not 
significantly different from the control value (P =0.48). 
Initial P d 2  
Initial average P I s ~  O2 for control conditions was 48.4 k 3.7 mmHg; for the low L- 
NAME (7 mgll) + papaverine PIsF O2 was 65.37 k 5.07 mmHg; for the intermediate L- 
NAME (10 mgll) and papaverine 44.0 k 3.6 mmHg, and L-NAME (30 mgll) + 
papaverine P1sFO2 was 40.3 2.7 mmHg. (Figure 14) The initial average PISFO2 for low 
dose of L-NAME + papaverine is significantly different from the control (P = 0.01), the 
intermediate L-NAME + papaverine dose (P = 0.005), and the high L-NAME + 
papaverine dose (P = 0.01). 
Minimum P zsflr 
There was no significant difference (p = 0.98) in the minimum PISFO2 among the 
different groups: Control (1.1 * 0.1 mmHg); L-NAME (7 mg/l) + papaverine 1.1 f 0.1 
mmHg; L-NAME (1 0 mgll) + papaverine was 1. I* 0.1 mmHg ; and L-NAME (30mgfl) 
+ papaverine 1.1 * 0.1 mmHg (Figure 14). 
Duration of Hypoxia 
The duration of hypoxia, for the high dose of L-NAME + papverine of 58 % 3 s 
was significantly different from the Control (48 * 1 s, P = 0.02) and the low dose of L- 
NAME + papaverine (45 * 4 s, P = 0.006) however is not significantly different from the 
intermediate dose of L-NAME + papaverine (5 1 * 1 s, P = 0.07) and there was no 
significant difference between any of the other conditions (Figure 15). 
Recovery Peak PzSf12 
The recovery peak PIS~02 for the control group was 70.9 * 3.0 mmHg , for the 
low dose L-NAME (7 mg/l)+ papaverine group it was 85.4 k 7.0 mmHg, for the 
intermediate dose L-NAME (10 mg/l) + papaverine group it was 66.1% 6.1 rnmHg, and 
for the high dose L-NAME (30 mgll) + papaverine group it was 50.85 f 5.43 mmHg 
(Figure 14). There were significant differences for recovery peak PISFOZ significantly 
decreased from control to L-NAME (30 mg/l) + papaverine (p = 0.04), from low L- 
NAME (7mgll) + papaverine to L-NAME (30 mgll) + papaverine (p = 0.004), and from 
L-NAME (7mgll) + papaverine to L-NAME (10 mgll) + papaverine (p = 0.03). 
The control mean diameter was 33.6 * 3.2 pm, for L-NAME (7 mgll) + 
papaverine mean diameter 35.3 * 4.3 pm, and L-NAME (10 mgll) + papaverine mean 
diameter was 29.1k 2.1 pm. The diameter change for L-NAME (10 mgll) + papaverine 
was - 0.195 h 0.097. Diameter change with L-NAME (10 mgll) + papaverine is not 
significantly different from zero. Baseline diameter measurements were not made in the 
experiments involving the L-NAME (7mgll) and papaverine dose. 
Control L-NAME 
Low 
GNAME 
Int. 
L-NAME 
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Figure 13. Effect of L-NAME on Oxygen Consumption 
L-NAME (lo mgA) + Papaverine 
L-NAME (30 mgA) + Papaverine 
8 
m. I 
Minimum Recovery 
Figure 14. Effect of L-NAME on PISFOZ 
The initial average PlsEOZ for intermediate dose of L-NAME + papaverine is 
significantly different fiom the control (P = 0.01), the low L-NAME + papaverine dose 
(P = 0.005), and the high L-NAME + papaverine dose (P = 0.01). There were significant 
differences for recovery peak PIsFOZ significantly decreased from control to L-NAME 
(30 mgll) + papaverine (p = 0.04), b r n  intermediate LNAME + papaverine to L-NAME 
(30 mgA) + papaverine (p = 0.004), and from L-NAME + papaverine to LNAME (10 
mgA) + papaverine (p = 0.03). 
L-NAME (7 @)+Papaverine 
L-NAME (1 Omgil)+Papaverine 
LNAME (JOmg/I)+Papaverine 
Control L N W  
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Figure 15. Effect of L-NAME on the Duration of Hypoxia 
LNAME (7 tng/l)+Papaverine 
LNAME (1 Omd) +Papaverhe 
Int. High 
Figure 16. Effect of LNAME on Mean Arteriolar Diameter 
Variables LNAME 10 rnm + Papaverine 
VO,, ml o2 . kg-'. min-' 6.80 0.35 5.86 * 0.50 
Initial PISFOZ, rnmHg 48.4 k 3.7 44.0 * 3.6 
Minimum P I S F ~ ~ ,  ~ltnHg 1.1 * 0.1 1.1* 0.1 
Duration of Hypoxia, sec 48 k 1 51 =k 1 
Recovery Peak PlSf12, mmHg 70.9 3.0 -_ - 66. l* 6.1 
Table 2. Effects of L-NAME under Saffan 
Effect of Carboxy-PTIO + papaverine 
vo2 
The control VO, was 5.88 * 0.47 m102 . kg-'- min-' and the Carboxy -PTIO + 
papaverine VO, was 4.94 f 0.39 m102 . kg-'- min-' . VO, with Carboxy-PTIO + 
papaverine is not significantly different from the control value (P = 0.085). 
Initial Pzsfla 
The control initial PISFO2 was 56.6 f 3.4 mmHg and for Carboxy -PTIO + 
papaverine initial PISF02 was 48.1 f 5.7 mrnHg. Initial PlSF02 with Carboxy-PTIO + 
papaverine was not significantly different (P = 0.14). 
Minimum P zSf12 
The control minimum PIsF02 was 1.0 f 0.6 mmHg and for Carboxy-PTIO + 
papaverine minimum PISFO2 value was 1.1 f 0.32 rnrnHg. Minimum PlSF02 with 
Carboxy-PTIO + papaverine was not significantly different (P = 0.28). 
Duration of Hypoxia 
The control duration of hypoxia 42 k 4 s and the Carboxy-PTIO + papaverine 
duration was 47 f 4 s. Initial PISFOZ with Carboxy-PTIO + papaverine is not significantly 
different from the control (P = 0.35). 
Recovery Peak P d Z  
The control recovery peak PISFOZ was 84.1 St 3.4 rnmHg and the Carboxy-PTIO + 
papaverine recovery peak PlSF02 was 71.0 h 8.0 mmHg. Initial PIsF02 with Carboxy- 
PTIO + papaverine is not significantly different from the control value (P = 0.08). 
Arterial Diameter 
The control mean diameter was 36.3 h 2.6 pm and the Carboxy -PTIO mean 
diameter was 33.0h 2.8 pm. The diameter change for Carboxy-PTIO was -0.14 h 0.05. 
Diameter change with Carboxy-PTIO + papaverine was significantly different from zero 
(P = 0.02). 
Control 
Figure 17. Effect of C-PTIO + PAPAVERINE on Oxygen Consumption 
Initial Minimum Recovery 
Figure 18. Effect of C-PTIO + PAPAVERINE on PIS,& 
Figure 19. Effect of C-PTIO + PAPAVERINE on Duration of Hypoxia 
Variables Control Carboxy - PTIO + Papaverine 
m, ml O2 • kg-'. mid 5.88 k 0.47 4.94 k 0.39 
Initial Plsf12, mmHg 56.6 f 3.4 48.1 * 5.7 
Minimum PI~@2, mmHg 1.0 f 0.6 1.1 h 0.32 
Duration of Hypoxia, see 4 2 h 4  47*4 
Recovery Peak PI~POZ, mmHg 84.1 f 3.4 71.0 * 8.0 
Table'3. Effects of C-PTIO 
Effect of Spermine NONOate 
The control VO, (4.9 1 k 0.22 m102 - kg-'. min") and for Spermine NONOate 
VO, (5.38 f 0.50 m102 . kg-'- min-') were not significantly different (P = 0.37) (Figure 
20). 
Initial P I d 2  
The initial PISFO2 for control (58.4 * 2.9 rnmHg) and for Spermine NONOate 
initial PISFO2 (56.6 f 3.5 rnrnHg. were not significantly different (P = 0.70) (Figure 21). 
Minimum P I d 2  
The minimum PISFOZ for control (1.09 * 0.07 mmHg) and Spermine NONOate 
minimum PISFOZ (1.6 1 f 0.54 mmHg) were not significantly different (P = 0.3 1) (Figure 
2 1). 
Duration of Hypoxia 
The duration of hypoxia for control (43 2. s) and Spermine NONOate (42 k 3 s) 
were not significantly different (P = 0.98) (Figure 22). 
Recovery Peak PIS& 
The recovery peak PISFOZ for control (79.1 f 3.3 rnrnHg) and for Spermine 
NONOate (80.3 f 5.34 rnmHg) were not significantly different (P = 0.84) (Figure 22). 
Arteriolar Diameter 
The mean diameter for control was 33.7 f 2.3 pm and for Spermine NONOate 
mean diameter was 3 1.8 f 2.8 p.m. The diameter change for Spermine NONOate was - 
0.08 f 0.07. Diameter with Spermine NONOate is not significantly different from zero 
(P = 0.27) (Figure 23, Figure 29). 
Spermine NONOate 
Figure 20. Effect of Spermine NONOate on Oxygen Consumption 
Spermine NONOate 
90 - 
Initial Minimum Recovery 
Figure 21. Effect of Spermine NONOate on PISF02 
Sperminc NONOate r r l  
0- 
Control 
Figure 22. Effect of Spermine NONOate on the Duration of Hypoxia 
Suermine NONOate 
Figure 23. Effect of Spermine NONOate on Mean Diameter 
Variables Control Spermine NONOate 
Initial PISf12, mrnHg 58.4 * 2.9 56.6 * 3.5 
Minimum P I S ~ O ~ ,  M g  1.09 k 0.07 1.61 k 0.54 
Duration of Hypoxia, sec 43 k 2 42 k 3 
Recovery Peak PISF02, mmHg 79.1 * 3.3 80.3 k 5.34 
Diameter Change, pm - - 0.08 k 0.07 
Table 4 Effects of Spermine NONOate 
Effect of Papaverine 
tVO2 
Control experiments in this group of animals (n = 4) exhibited VO, of 5.36 f 0.24 
ml 0 2  . kg-'. min-'. In the same animals V O ~  value was 5.3 1 h 0.3 1 ml 0 2  . kge'. min-' 
after treatment with papverine. The two values were not significantly different (P = 0.93) 
(Figure 24). 
Initial Pzsf12 
The initial P I ~ F O ~  for control (53.2 * 3.6 rnmHg) and papaverine (52.9 * 4.2 
mmHg) were not significantly different (P = 0.28) (Figure 25). 
Minimum PzSf12 
The minimum PISF02 for control (1.1 f 0.1 mmHg) and papaverine (1.0 h 0.1 
mmHg) were not significantly different (P = 0.92) (Figure 25). 
Duration of Hypoxia 
The duration of hypoxia for control (41 h 1 s) and papaverine duration (46 f 3 S) 
were not significantly different (P = 0.92) (Figure 26). 
Recovery Peak PISr;02 
The recovery peak PISFO2 for control (82.7* 8.2) mmHg and papaverine (84.3 * 
6.0 mmHg) were not significantly different (P = 0.80) (Figure 26). 
Arteriolar Diameter 
The mean diameter for control was 38.3 * 4.9 pm and the papaverine mean 
diameter was 30.0 h 2.3 pm. The diameter change for papaverine was 0.1 8* 0.1 6. 
Diameter change with papaverine was not significantly different from zero (P = 0.32) 
(Figure 27, Figure 29). 
Control Papaverine 
Figure 24. Effect of Papaverine on Oxygen Consumption 
Figure 25. Effect of Papaverhe on PISFO2 
Minimum Rec 
- 
Control 
Figure 26. Effect of Papaverine on the Duration of Hypoxia 
Control Papaverine 
Figure 27. Effect of Papaverine on Arteriolar Diameter 
p Pa averine 
V@ , mlO2 - kg-'- min-' 5.36 * 0.24 5.31 * 0.31 
Initial PISFOP, mmHg 53.2 * 3.6 52.9 * 4.2 
Minimum PISF02, fnrnHg 1.1 * 0.1 1.0 * 0.1 
Duration of Hypoxia, sec 41 * 1 46 * 3 
Recovery Peak PISf12, mmHg 82.7* 8.2 84.3 * 6.0 
Diameter Change, pm - 0.18h 0.16 
Table 5 Effects of Papaverine 
Control 
CNAME (1 0 mgll) 
L-NAME + Papaverine 
Carboxy-PTIO 
Srrmine NONOate 
Papaverine 
. 
-,.--. -..- , -..,.&..., k L-NAME PSavainc Plpvainc PIpVsiae C-PTIO 
L O W I H T m  
Figure 28. Effect of Various Treatments on Oxygen Consumption 


















Appendix I1 
PENTOBARBITAL PILOT STUDY 
PO2 Time Recove Time 
h!S - -  dP02ldt VO2 0 - sD " fmmHp1 l m m g )  9 1 c 2 s PeakP02 ly fl s bu! DC02 ee2 
20106 0.00 
Baseline A -5.62 9.81 87.28 i 829  152-210 59 0.43 161 96.02 27 1 
Baseline B -6.50 11.35 94.39 * 12.17 0 10.18 182 145.83 255 
Baseline C 0.00 f 
22306 
BaselineA2 4.05 7.06 57.57 * 3.52 7.37 36.2 139-189 51 0.00 143 61.92 224 
BaselineB2 -4.02 7.02 52.93 i 3.03 145-203 59 0.16 187 59.48 276 
BaselineD2 -3.15 5.50 50.36 2.16 145-192 48 0.82 160 52.80 245 
22506 
BasclineA2 -1.15 2.01 81.54 * 10.42 7.44 26.9 99.4 80.6 5.8 151-185 35 1.24 179 93.11 289 
BasclineB2 -2.21 3.86 50.35 * 8.06 29.2 1.4 139-185 47 0.05 179 79.04 229 
;BaselineC2 -2.77 4.83 77.75 * 5.77 50.4 1.4 152-184 33 1.03 181 80.78 296 
BaselineE2 -2.12 3.70 64.73 6.96 35.2 139-185 47 2.75 147 79.50 250 
BaselineF2 -5.04 8.79 69.68 * 4.24 39.8 6.7 219-278 60 1.69 222 91.61 336 
30206 
BaselineA2 4.37 7.63 75.09 * 8.79 7.39 34.4 89.5 145-189 45 1.18 157 84.58 233 
BaselineB2 -1.51 2.63 44.81 * 2.73 135-188 34 0.09 141 64.39 218 
BaselineC2 -5.78 10.08 61.36 f 4.48 137-184 48 1.27 153 85.04 211 
L-NAME 1 A -1.69 2.95 30.99 f 2.12 134-183 50 1.02 180 53.40 193 
L-NAME 1 B -4.23 7.39 35.23 * 4.15 179-234 58 0.37 212 42.05 289 
L-NAME 1 C -5.30 9.25 36.57 * 8.89 130-193 64 1.32 158 82.44 262 
L-NAME 2 A -2.27 3.97 56.89 f 2.93 151-183 33 2.15 182 70.62 224 
L-NAME 2 C -2.90 5.06 27.19 * 3.04 130-200 71 1.08 168 38.28 232 
30306 
BaselineA2 -4.05 7.07 67.09 * 7.65 141-182 42 124  163 74.93 25 1 
BaselineE2 -3.13 5.47 34.22 * 5.41 133-188 56 1.27 164 58.68 295 
BaselineFZ -3.68 6.42 60.11 * 11.09 135-185 51 1.16 154 59.69 280 
BaselineG2 -4.23 7.38 50.41 * 2.95 135-186 50 1.10 180 52.65 267 
Dose 1 A2 -2.63 4.59 32.51 * 2.81 133-185 53 1.17 157 28.88 263 
DoselH2 -2.59 4.52 24.74 * 3.09 133-193 61 0.89 166 28.68 26 1 
Control AVG: 6.51 63.51 45.00 1.51 167.82 77.65 260.35 
Control SD: 2.63 16.05 14.27 2.34 20.18 22.67 33.11 
Control SE: 0.62 3.78 3.36 0.55 4.76 5.34 7.80 
L-NAME(1Oe)  AVG: 5.74 32.01 57.20 0.95 174.60 47.09 253.60 
L-NAME(~OU@L) SD: 2.17 10.57 12.19 0.54 19.09 20.76 31.90 
LNAME(10mglL) SE: 0.97 4.73 5.45 0.24 8.54 9.28 14.27 
LNAME (30mgL) AVG: 4.52 42.04 52.00 1.61 175.00 54.45 228.00 
L-NAME (30mgL) SD: 0.78 21.00 26.87 0.76 9.90 22.87 5.66 
L-NAME ( 3 0 w )  SE: 0.55 14.85 19.00 0.53 7.00 16.17 4.00 
GNAME + PAPAVERME 
Initial 
-
Date 
-
dPOYdt a! l a m  Ius P P 2 I d 2 E T i m e  
PO2 
Baseline F -2.86 
L-NAME 1 F -2.13 
Baseline A 
Baseline B 
Baseline C 
L-NAME+Papa 1 A 
LNAME+Pspa 1 B 
LNAME+Pspa 1 C 
32106 
Baseline A 
Baseline B 
Baseline D 
Baseline E 
Baseline F 
LNAME+Pape 1 A 
L-NAME+Papa I B 
L-NAME+Papa 1 C 
L-NAME+Papa I D 
L-NAME+Papa I E 
L-NAME+Papa 2 A 
L-NAME+Pv 2 B 
L-NAME+Papa 2 C 
L-NAME+Papa 2 D 
32806 
Baseline A 
Bascline B 
Baseline C 
Baselk D 
Bsseline E 
Baseline F 
L-NAME+Papa l A 
LNAME+Pnpa 1 B 
L-NAME+Papa I C 
8.00 UTA UTA 
13.07 
4.86 
5.99 
4.09 
8.43 
UTA 36.8 
83.5 
48.5 
25.5 
34.6 
25.9 
Baseline A -4.13 7.21 47.05 i 250 7.44 36.6 114 30.6 4 135-185 51 1.14 155 69.93 217 
Baseline B -3.34 5.83 42.69 i 4.92 30.6 4 138-182 45 1.04 154 67.15 187 
Baseline C -3.99 6.97 45.16 * 5.03 35.2 6 133-185 53 60.5 1 202 1.09 145 
Baseline D -3.31 5.78 34.32 i 4.08 26.8 14.3 132-189 58 1.64 181 4432 249 
Baseline E -5.25 9.16 63.01 * 7.11 16.4 7.8 131-185 53 1.37 179 74.14 215 
Baselk F -4.07 7.10 30.39 i 2.28 11.7 6.2 137-192 58 1.28 170 37.40 247 
LNAME+PalM 1 A -2.58 4.50 37.74 i 2.83 7.48 31.2 86 492 2 132-184 53 1.55 169 46.79 207 
L-NAME+Pq 1 D -3.70 6.45 25.41 i 4.91 24.5 3.5 132-188 57 1.21 154 35.79 272 
40106 
L-NAME+Papa A -2.79 4.87 63.43 i 63.43 7.37 50.7 85 37.7 155-182 28 1.38 181 100.88 212 
L-NAME+P+ B -2.97 5.18 70.86 i 12.18 35.9 1.2 138-185 48 1.08 171 96.02 224 
L-NAME+Papa C -3.84 6.71 77.83 i 16.01 37.4 235 137-185 49 1.17 163 100.17 291 
L-NAME+P+ D -3.52 6.15 42.73 i 5.00 51.4 252 131-186 56 0.77 171 57.23 205 
L-NAME+Papa E 4.57 7.97 63.80 6.35 30.6 29.8 136-183 48 1.09 171 74.77 221 
L-NAME+Papa F 4.25 7.42 73.58 i 12.15 7.45 37.4 90.6 18.9 17.3 142-184 43 1.10 175 83.23 289 
Control AVC: 6.80 48.40 33.67 8.97 48.76 1.13 165.81 70.91 230.19 
Control SD: 1.59 17.15 , 14.64 5.89 6.36 029 12.36 13.88 29.18 
Control SE: 0.35 3.74 3.20 1.29 1.39 0.06 2.70 3.03 6.37 
L - N w l o & ) + P l p l  AVG: 5.86 43.95 29.06 8.72 50.85 1.09 167.31 66.07 230.31 
L-NAME(lOmg/L)+Papa SD: 1.81 13.12 7.49 6.92 5.26 0.37 8.61 21.93 24.70 
L - N ~ l ~ ) + P a p a  SE: 0.50 3.64 2.08 1.92 1.46 0.10 2.39 6.08 6.85 
GNAME+Papa AVC: 6.38 65.37 35.32 19.40 45.33 1.10 172.00 85.38 240.33 
L-NAME+Papa SD: 1.22 12.42 10.59 11.12 9.46 0.19 5.90 17.22 39.06 
GNAME+Papa SE: 0.50 5.07 4.32 4.54 3.86 0.08 2.41 7.03 15.95 
GNAME (3Omg/L)+Papa AVG: 629 40.27 39.95 13.50 58 1.08 156.50 50.85 266 
GNAME (3Omg/L)+Papa SD: 2.38 9.67 5.76 3.39 9.38 0.19 6.56 19.61 21.40 
GNAME (30m@)+Papa SE: 0.66 2.68 1.60 0.94 2.60 0.05 1.82 5.44 5.94 
M A M E  DIAMETER 
Date Baseline d Treatment dT 
31606 
Baseline F 
31706 
Baseline A 
Baseline B 
Baseline C 
32106 
Baseline A 
Baseline B 
Baseline D 
Baseline E 
Baseline F 
L-NAME I F 
32806 
Baseline A 
Baseline B 
Baseline C 
Baseline D 
Baseline E 
Baseline F 
33006 
Baseline A 
Baseline B 
Baseline C 
Baseline D 
Baseline E 
Baseline F 
L-NAME+Papa A 37.7 
L-NAME+Papa B 35.9 
L-NAME+Papa C 37.4 
L-NAME+Papa D 5 1.4 
L-NAME+Papa E 30.6 
L-NAME+Papa F 18.9 
Control AVG: 33.7 LNAME(lOmg/L)+Papa AVG: 29.06 AddB AVG: -0.20 
Control SD: 14.6 L-NAME(lOmg/L)+Papa SD: 4.30 AdldB SD: 0.34 
Control SE: 4.06 L-NmE(lOmg/L)+Papa SE: 1.19 AdldB SE: 0.10 
L-NAME(7mg/L)+Papa AVG: 35.32 
L-NAME(7mglL)+Papa SD: 10.59 
L-NAME(7mg/L)+Papa SE: 4.32 
LNAME (3Omg/C)+Papa AVG: 39.95 AddB A v c :  0.20 
L-NAME (30mg/e)+Papa SD: 5 -76 ~ d / d ~  SD: 0.36 
L-NAME (30mg/L)+Papa SE: 2-88 A ~ I ~ B S E :  
- - 
- - - -  - 
0.2 1 
- 
- 
- 
CARBOXY-PTIO 
m 
d P 0 2 / d t l r q Z m e r n  ., & a  laf,,,dEl g s s i i i z k g P Z L r l  pot M 21, m2 m r n  
52806 
BasalineA -5.78 10.08 72.07 ;t 5.11 103 274 7.30 42.4 115 29.1 17.69 137-185 49 0.91 161 84.18 216 
BaselineB 4.66 8.13 88.47 f 5.72 7.29 46.1 110 21.3 2.9 139-188 50 0.86 165 97.68 242 
B ~ l i n o C  -3.67 6.41 54.66 4 4.28 452 9.7 135-188 54 0.83 150 11 1.64 225 
BaselincD -4.77 8.32 50.87 * 6.11 49.2 4.09 134-184 51 1.22 148 79.65 211 
BasalineE 4.33 7.56 37.78 * 7.15 44.1 2.3 134-185 52 0.88 164 68.79 200 
BasclineF 4.34 7.58 37.86 * 18.80 41.8 4.58 102-139 38 1.65 106 81.29 253 
Carboxy PTIO A 4.85 8.46 19.12 f 1.58 UTA UTA 7.54 36.6 99.9 23.1 10.02 130-205 76 0.74 177 14.90 297 
Carboxy PTIO B -2.58 4.51 59.48 i 5.12 22 1.9 143-189 47 0.53 153 69.39 268 
Carbo~yPTI0 C -1.76 3.08 28.94 * 2.52 30.9 12.22 134-191 58 0.54 167 37.83 262 
Carboxy PTIOD -3.61 6.30 41.54 i 2.53 UTA UTA 135-186 52 1.00 181 60.95 231 
Carboxy PTIO E -3.39 5.92 44.21 * 3.05 UTA UTA 136-185 50 0.69 164 59.41 220 
&&JXY PTIOF -2.96 5.16 38.35 * 2.74 30.4 9.06 135-186 52 2.77 171 47.70 295 
C h x y  P110 G -3.25 5.68 59.12 * 4.52 23.1 10.02 135-184 50 0.72 179 86.02 244 
Cahoxy PTIO H -3.37 5.87 42.20 * 3.24 30.4 9.06 136185 50 1.58 170 52.57 288 
53006 
BaselineA -1.29 2.25 79.10 * 3.75 92.8 40.3 27.8 0 5.1 1 192 94.68 229 
Bascline3 -2.24 3.90 66.44 i 3.24 22 1.67 149-184 36 0.80 172 76.19 207 
BacclineC -2.85 4.97 38.05 * 2.57 44.6 5.1 139-183 45 0.55 159 83.37 217 
BkselineD -2.82 4.91 65.61 * 6.08 37.1 24.35 142-202 61 0.73 168 106.32 263 
BwlincE -3.83 6.68 59.96 * 4.62 47.4 19.85 14&1&1 45 0.92 160 93.66 207 
Baselin& -3.58 6.25 72.78 * 5.63 26.1 9.44 142-185 44 0.94 173 97.28 225 
Cahoxy PTIO A -1.65 2.88 72.35 i 6.00 78.3 38.9 24.6 157-185 29 0.31 177 83.64 291 
Cdwxy IT10 B -2.27 3.97 39.93 3.26 UTA UTA 145-185 41 0.16 170 80.98 277 
C&xyPTIOC -1.86 335 77.60 * 11.74 40.3 14.9 0 5.25 193 120.19 245 
C ~ J O X ~  PTIO D -3.47 6.06 70.45 * 8.62 39.7 19.6 142-184 43 0.10 150 123.02 268 
Carboxy PTIO E -3.38 5.89 82.93 * 8.77 42.2 20.2 143-185 43 0.79 182 11 1.36 246 
Ca150xy PnO F -2.60 4.54 58.85 * 8.04 31.2 15.5 141-184 44 0.56 177 84.06 201 
Carboxy PTIO G -2.86 4.98 53.26 * 5.38 36.5 17.2 147-186 39 0.53 172 79.50 224 
Carboxy P n O  H -3.36 5.86 85.36 * 12.27 39.7 19.6 150-182 33 0.68 170 111.33 256 
61506 
B ~ s ~ ~ u A  -1.60 2.79 58.06 i 5.70 77.1 53.91 60.08 0 10.97 182 78.40 219 
BaselineB -3.38 5.90 56.94 i 5.24 40.4 13.5 145-187 43 1.11 155 87.28 248 
BaselineC -3.32 5.80 52.65 * 5.59 18.3 3.64 151-196 46 0.95 192 83.76 228 
BwlineD -2.83 4.93 41.49 i 2.92 42 12.8 141-189 49 1.27 162 64.04 215 
BaselineE -2.32 4.05 41.30 * 4.08 20.6 1.75 142-188 47 1.63 184 57.62 205 
BaseheF -3.12 5.45 45.24 4 5.54 30.2 11.9 144-193 50 0.71 161 67.21 210 
Ckboxy PTIO A -2.38 4.16 32.97 * 2.68 94.6 405 7.38 33.7 72.3 40.4 10 144-206 63 0.75 185 60.56 226 
Carboxy PTIOB -2.19 3.82 28.49 * 3.45 38.7 7.4 130-186 54 0.97 136 58.22 210 
C h b ~ x y  PTIO C -3.73 6.51 32.30 * 3.07 9 3.04 141-193 52 1.23 74 45.21 202 
Carboxy PTIO D -2.1 1 3.69 24.11 * 2.27 39.9 7.73 131-185 54 1.50 162 53.49 202 
Carboxy PTIO E 
. -. 
Carboxy PnO F -2.27 34.77 + 2.95 18.3 7.16 135-182 48 2.33 152 51.54 197 
Carboxy PTIO G i 41.9 
Carboxy PTIO H -2.43 31.79 * 4.16 47 1 43.1 7.07 134-185 52 1.17 142 69.37 213 
Control AVG: 56.63 99.3 36.3 1 42.22 1.78 164.1 1 84.06 223.33 
Control SD: 15.16 4.04 11.11 16.37 2.46 19.42 14.49 17.82 
Control SE: 0.47 3.57 0.95 2.618 3.86 0.58 4.58 3.42 4.20 
CarboxyPTIO AVG: 4.94 48.10 94.3 32.99 46.82 1.13 163.82 70.97 243.77 
Cnrboxy PTIO SD: 1.36 19.88 0.42 9.518 14.33 1.12 24.58 27.69 33.41 
Carbory PTIO SE: 0.39 5.74 , 0.12 2.748 4.14 0.32 7.10 7.99 9.64 
CARBOXY-lTIO DIAMETER 
Date - Baseline - dB Treatment - dT - Ad 
52806 
BaselincA 29.1 Carboxy PTIO A 23.1 -6 -0.21 
BasclineB 2 1.3 Carboxy PTIO B 22 0.7 0.03 
BasclineC 45.2 Carboxy PTlO C 30.9 -14.3 -0.32 
BasclineD 49.2 Carboxy PTIO D UTA 
BasclineE 44.1 Carboxy PTIO E UTA 
BasclineF 4 1.8 Carboxy PTIO F 30.4 
Carboxy PTIO G 23.1 
Carboxy PTIO H 30.4 
BaselincA 
BasclincB 
BasclineC 
BasclineD 
BasclincE 
BasclineF 
61506 
BasclineA 
BaselineB 
BaselineC 
BasclincD 
BasclineE 
BaselineF 
40.3 Carboxy PTIO A 
22 Carboxy PTIO B 
44.6 Carboxy PTIO C 
37.1 Carboxy PTIO D 
47.4 Carboxy PTIO E 
26.1 Carboxy PTIO F 
Carboxy PTIO G 
Carboxy PTIO H 
38.9 
UTA 
40.3 
39.7 
42.2 
31.2 
36.5 
39.7 
53.9 1 - Carboxy PTIO A 40.4 -13.51 -0.25 
40.4 Carboxy PTIO B 38.7 -1.7 -0.04 
18.3 Carboxy PTIO C 9 -9.3 -0.51 
42 Carboxy PTIO D 39.9 -2.1 -0.05 
20.6 Carboxy PTIO E 
30.2 Carboxy PTIO F 18.3 -11.9 -0.39 
Carboxy PTIO G 41.9 
Carboxy PTlO H 43.1 
Control AVG: 36.3 1 CnrboxyPnO AVG: 32.99 AdldB AVG: -0.14 
Control SD: 1 1.1 1 Cnrboxy PTIO SD: 9.52 AddBSD: 0.19 
Coabol SE: 2.62 Cnrboxy PTIO SE: 2.75 AddBSE: 0.05 
- 
IJ&!&I Reeoveq 
SD M A P  oC02 a D.tc d P O U e t m m  - - Time 
2 { m m )  { r n ~  1 Y Y B l L P 1 1  y a 
51686 
BaselineA -2.13 3.72 67.18 4.78 7.301 48.3 92.6 19.7 148-180 33 0.98 164 86.67 224 
BaselineB -1.68 2.93 5327 * 4.00 37.9 9.98 151-184 34 1.21 182 73.09 247 
B ~ e l i n d :  -2.59 4.51 61.12 6.07 30.3 18.16 148-183 36 1.62 169 76.49 217 
BaselineD -2.59 4.51 60.04 * 3.48 32.1 16.61 151-182 32 1.41 178 86.42 217 
BarelincE -2.62 4.57 57.54 + 4.35 16.1 9.05 187-141 47 1.52 181 64.82 226 
B l ~ ~ d h &  -2.41 4.21 57.37 * 7.81 32.9 5.62 155-199 45 1.30 179 74.17 264 
SPWWNOA -1.79 3.13 48.71 * 4.14 81.8 28.5 8.17 4.12 160 112.35 500 
SpcnnMOB -2.15 3.75 46.08 * 3.16 44.8 11.99 138-185 48 1.39 182 50.10 273 
S-OC -2.41 4.20 38.82 * 5.74 28.4 3.11 137-189 53+3 1.15 160 34.65 276 
S-OD -3.31 5.77 39.33 * 4.52 17 2.85 136-188 53 1.39 166 63.26 280 
SpermMOE -3.60 6.28 48.60 * 3.79 14.1 1.61 145-199 55 0.74 192 61.39 243 
S-OF -5.44 9.50 50.10 * 5.49 121 370 24.6 14.84 135-186 52 1.23 179 77.84 233 
51806 
BaselineA -3.55 6.19 72.62 i 5.99 86 201 7.275 97 36.8 2.17 141-190 50 0.77 164 106.26 262 
BasclineB -2.80 4.88 72.86 * 5.63 94 236 38.8 7.7 147-185 39 0.73 183 106.64 234 
BaselinaC -2.69 4.69 65.97 * 3.00 41.1 17.1 144-184 41 1.73 183 78.11 277 
BaseliieD -2.22 3.88 55.36 * 2.71 84 299 35 7.85 146-187 42 0.79 165 78.87 242 
BasclincE -3.02 5.26 59.75 * 3.42 31.2 2.97 142-187 46 0.90 157 71.06 243 
BaselineF -3.10 5.41 77.09 * 4.47 101 338 46 11.33 143-184 42 1.12 173 94.81 207 
S p c d O A  -1.99 3.47 69.69 * 7.17 7.408 75.7 61 3.85 0 10.78 181 89.13 247 
S-OB -2.35 4.09 53.83 * 8.15 39.4 6.46 141-185 45 0.69 176 96.21 217 
SpermMOC -3.08 5.38 38.92 * 7.04 107 366 35.8 11.17 135-183 49 0.83 148 89.42 201 
SpcnnMOD -2.64 4.61 65.93 * 8.08 30.6 5.46 140-184 45 1.12 176 97.85 224 
Sperm/NOE -3.80 6.63 68.63 * 8.69 30.1 5.21 137-183 47 0.63 163 100.13 208 
S p d O F  -4.91 8.57 83.65 * 12.55 107 378 21.2 12.1 138-182 45 1.09 180 129.46 255 
52306 
BasetincA -3.65 6.38 60.94 * 5.94 106 365 7.313 122 41.6 10.5 142-184 43 1.12 180 88.90 211 
BeselineB -3.64 6.35 66.23 * 7.04 103 375 7.348 113 48.2 11.2 143-183 41 1.03 170 105.49 215 
BaseheC -3.76 6.57 28.80 * 4.44 29 13.1 133-186 54 0.88 171 70.62 235 
BaselineD 0.00 i 18 7.08 
BaselineE -3.68 6.43 14.89 * 3.02 18 7.08 127-204 78 0.43 159 39.13 295 
52606 
BaselineA -2.32 4.05 65.87 * 5.46 106 311 7.391 40.7 60.7 45.8 23.2 149-185 37 1.14 168 70.71 211 
- . ., . .. 
Baseline3 -3.00 5.24 55.48 i 2.69 39.: 47 1.03 177 68.07 275 
. - 
B ~ l i n s C  -2.81 4.90 59.56 * 3.99 35 1.56 181 77.06 237 
BasclineD -2.84 4.95 59.54 + 3.88 43 0.93 152 80.08 214 
Baselin& -1.73 3.02 56.60 * 3.06 33 1.00 174 71.90 227 
BasalineF -3.10 5.42 55.72 * 3.27 93 392 41-1' 43 0.75 164 70.66 229 
Sperm/NOA -2.56 4.46 62.46 * 5.22 108 371 7.475 147-18 I 40 0.54 177 78.90 225 
SpermMOB -2.38 4.16 70.39 * 7.20 145-183 38 0.73 163 93.19 235 
Sperm/NOC -3.91 6.82 26.77 3.43 133-186 54 1.02 151 43.58 292 
S-OD -3.17 5.54 63.38 * 8.13 114 419 137-183 47 0.50 170 73.32 205 
S p e W O E  -1.42 2.49 60.25 * 4.33 r r.-tj 159-183 25 0.84 179 78.17 247 
Sperm/NOF -1.84 3.22 59.95 * 3.26 424 32 0.87 176 71.31 238 1 0.5 152-183 
S-OG -5.83 10.18 80.47 * 11.44 44.3 10.1 141-183 43 0.97 167 85.84 253 
Control AVG: 4.91 58.35 33.7 42.77 1.09 171.55 79.09 236.77 
Control SD: 1.05 13.55 10.8 9.80 0.33 9.11 15.39 24.35 
Control SE: 0.22 2.89 2.3 2.09 0.07 1.94 3.28 5.19 
SpendNO AVG: 5.38 56.63 31.8 42.24 1.61 170.84 80.32 255.37 
SpermfNO SD: 2.18 15.10 12 13.39 2.35 11.36 23.44 64.62 
Sperm/NO SE: 0.50 3.46 2.75 3.07 0.54 2.61 5.38 14.82 
SPERMINE NONOATE DIAMETER 
Date Basebe - dB Treatment a - Ad AddB 
51606 
BaselineA 
BaselineB 
BaselineC 
BaselineD 
BaselineE 
BaselineF 
51806 
BaselineA 
BaselineB 
BaselineC 
BaselineD 
BaselineE 
BaselineF 
52306 
BaselineA 
BaselineB 
BaselineC 
BaselineD 
BaselineE 
52606 
BaselineA 
BaselineB 
BaselineC 
BaselineD 
BaselineE 
BaselineF 
Control AVG: 33.7 
Control SD: 10.8 
Control SE: 2.3 
Sperm/NOA 
SpermNOB 
Sperm/NOC 
SpermINOD 
S W O E  
SpedNOF 
Sperm/NOG 
Spenn/NO AVG: 
SpemdNO SD: 
S~errn/N[O SE: 
AdldB AVG: -0.08 
AdldB SD: 0.29 
AdldB SE: 0.07 
PAI E 
1nitf.l 
- HR a Beeoveq Date dP02ldt mua 
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42106 
Papa A 
Papa B 
Papa C 
Papa D 
Papa E 
Papa F 
L-NAME A 
L-NAME B 
L-NAME C 
L-NAME D 
L-NAME E 
L-NAME F 
42506 
Papa A 
50206 
Baseline A -3.34 5.82 71.92 * 6.71 49.3 144-1 89 0.89 173.00 87.82 216 
Baseline B -2.84 4.96 39.37 i 2.87 23.2 146-190 1.12 183.00 61.24 271 
Baseline C -2.65 4.62 47.75 i 5.26 24.4 148-191 0.84 161.00 96.37 214 
Baseline D -3.56 6.21 50.27 i 10.98 23.5 139-184 1.27 158.00 96.52 21 1 
Baseline E -3.03 5.29 48.21 i 5.75 23.1 140-188 0.89 163.00 104.80 209 
Baseline F -3.07 5.36 53.07 i 6.29 27.2 139-185 0.74 168.00 93.95 225 
PapaSite A -2.67 4.65 57.88 i 7.65 44.2 144-190 0.91 157.00 85.16 221 
PapaSite B -3.84 6.71 63.39 i 11.40 17.4 140-183 1.78 157.00 86.40 275 
PapaSite C -3.61 6.31 37.56 i 6.04 38.2 237-295 1.57 252.00 84.87 380 
51106 
Baseline A -2.25 3.92 48.15 i 3.29 105 258 7.27 53.7 71.6 32.11 141-183 0.69 162.00 99.94 216 
Baseline B -2.65 4.63 48.69 * 3.21 31.3 11.16 136188 1.55 180.00 1.68 148 
Baseline C -3.81 6.65 80.39 i 6.19 32.4 13.99 1.68 148.00 79.00 303 
Baseline D -3.60 6.28 63.62 k 7.52 63.5 20.1 1.05 179.00 100.56 216 
Baseline E -2.62 4.57 39.53 i 2.64 52.4 21.74 0.96 188.00 78.61 203 
Baseline F -3.43 5.98 47.97 k 8.00 37.5 11.18 0.98 182.00 91.84 216 
Papa A -1.85 3.23 82.28 * 11.88 107.84 355 7.43 35.7 982 46.2 30 169-184 16 1.00 179.00 106.07 294 
- 
- - .- 
Papa B -2.30 4.02 18.98 + 5.10 37.4 142-188 48.79 194 
Papa C -3.42 5.96 23.78 * 2.22 37.4 132-184 10 20.72 286 
Papa D 4.41 7.70 53.19 5.56 44.8 28.22 138-184 10 99.82 199 
Papa E -2.03 3.54 32.01 + 4.09 40.9 22.06 133-189 10 44.48 212 
Papa F -2.84 4.95 39.16 * 3.88 30.4 9.98 136-186 10 93.80 206 
Papa G -2.65 4.62 53.39 * 4.60 17.7 2.02 140-184 45 178.00 86.54 204 
Papa H -2.64 4.60 39.50 * 3.91 31.3 16.27 153-199 47 191.00 
Control AVG: 5.36 53.24 38.28 46.63 i 170.42 82.69 220.67 
Control SD: 0.84 12.48 16.9 3.16 0.31 12.25 28.24 3728 
Control SE: 0.24 3.60 4.879 0.91 0.09 3.54 8.15 10.76 
Papaverine AVG: 5.31 52.87 36.01 45.83 1.04 176.22 84.30 236.88 
Papaverine SD: 1.32 17.99 9.881 10.77 0.31 2322 25.29 47.92 
Papaverine SE: 0.31 4.24 2.329 2.54 0.07 5.47 5.96 11.30 
L-NAME AVG: 6.32 72.00 36.88 42.83 0.85 171.33 110.79 243.83 
LNAME SD: 1.10 18.92 5.162 5.85 0.18 8.07 23.09 41.87 
GNAME SE: 0.45 7.72 2.107 2.39 0.07 3.29 9.42 17.09 
PAPAVERINE DIAMETER 
Baseline - d Treatment - dT - Ad AdIdB 
42106 
42506 
Papa A 
50206 
Baseline A 
Baseline B 
Baseline C 
Baseline D 
Baseline E 
Baseline F 
51106 
Baseline A 
Baseline B 
Baseline C 
Baseline D 
Baseline E 
Baseline F 
Papa A 
Papa B 
Papa C 
Papa D 
Papa E 
Papa F 
L-NAME A 
L-NAME B 
L-NAME C 
L-NAME D 
L-NAME E 
L-NAME F 
49.3 PapaSite A 
23.2 PapaSite B 
24.4 PapaSite C 
23.5 
23.1 
27.2 
71.6 Papa A 46.2 
31.3 Papa B 37.4 
32.4 PapaC 37.4 
63.5 PapaD 44.8 
52.4 PapaE 40.9 
37.5 PapaF 30.4 
Papa G 17.7 
Papa H 31.3 
Papaverine AVG: 36.01 
Control AVG: 38.28 Papaverine SD: 9.88 
Control SD: 16.9 Papaverine SE: 2.40 
L-NAME AVG: 36.88 
LNAME SD: 5.16 
GNAME SE: 2.1 1 
AdIdB AVG: 
AdIdB SD: 
AdIdB SE: 

